Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552261 | 0.91 | DDX3X (0.46) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL20552806 | 0.89 | ABCG2 (0.43) | KMT2AMEN1HSD17B10TP53ALDH1A1 | |
| SCHEMBL26615002 | 0.88 | TP53 (0.57) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL26615021 | 0.88 | TP53 (0.54) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL30603078 | 0.88 | TP53 (0.54) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL20553129 | 0.82 | HPGD (0.61) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL21749252 | 0.82 | TP53 (0.51) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL20552675 | 0.81 | TP53 (0.52) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL20552450 | 0.81 | DDX3X (0.47) | KMT2AMEN1HSD17B10TP53KDM4E | |
| SCHEMBL21764792 | 0.80 | ABCG2 (0.42) | ALDH1A1MAPTLMNASMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-07-03 | — | — | US | disclosed |
| WO-2025088571-A1 | CRYSTALLINE FORMS OF TEAD INHIBITOR | ASTRAZENECA AB (SE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4514793-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-04-11 | — | — | US | disclosed |
| WO-2023209084-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209088-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | CYP1B1, CYP2D6, CYP1A1 | KMT2A 2280/4885MEN1 572/4885HSD17B10 217/4885 |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, SDHA | KMT2A 1359/4885MEN1 1054/4885HSD17B10 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.